查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球失智症運動障礙治療症候群市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按用於治療的藥物、按地區
市場調查報告書
商品編碼
1410525

全球失智症運動障礙治療症候群市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按用於治療的藥物、按地區

Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 82 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

近年來，治療癡呆症和運動障礙相關綜合徵的全球藥物市場經歷了顯著增長。癡呆症是一種廣泛的精神疾病，以及包括帕金森氏症在內的運動障礙，給世界各地的患者和照護者帶來了重大挑戰。最近的數據顯示，大約 80% 患有帕金森氏症等運動障礙的人最終會出現認知障礙，這進一步凸顯了有效治療的必要性。

世界各地人口老化是癡呆症患者數量增加的動力。病例激增促使醫療保健提供者探索各種解決方案，包括家庭護理服務、成人日托服務、心理治療、藥物治療以及為晚期癡呆症患者量身定制的醫療設備。為了滿足患者及其家人的需求，安寧療護單位也大幅成長。

然而，儘管努力減輕癡呆症和運動障礙患者的負擔，但仍存在一些挑戰。這些挑戰包括嚴格的監管框架、藥物審批過程中的官僚障礙、缺乏研發資金以及尋找有效治療管理的持續努力。值得注意的是，大多數旨在治療這些疾病的藥物未能通過 III 期試驗，為尋找可行的治療方法造成了困難。

該報告研究了全球癡呆症運動障礙治療綜合症市場，並提供了市場概況，包括用於治療的藥物的趨勢、區域趨勢以及進入市場的公司的競爭趨勢。

目錄

第一章執行摘要

第二章市場概況

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • COVID-19 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • PESTLE分析

第三章全球治療症候群、失智症與運動障礙市場展望，2018-2031

  • 全球癡呆症運動障礙治療綜合症市場前景（按用於治療晚期癡呆症的藥物劃分），價值（十億美元），2018-2031 年
  • 全球癡呆症運動障礙治療綜合症市場前景（按用於治療伴有其他神經異常的晚期癡呆症的藥物），價值（十億美元），2018-2031 年
  • 全球癡呆症運動障礙治療綜合症市場前景（按用於治療運動障礙綜合症的藥物劃分），價值（美元），2018-2031 年
  • 全球治療症候群、失智症和運動障礙市場展望，按地區、價值（十億美元），2018-2031 年

第四章北美失智症運動障礙治療症候群市場展望，2018-2031

第五章歐洲失智症運動障礙治療症候群市場展望，2018-2031

第六章亞太地區失智症運動障礙治療症候群市場展望，2018-2031

第七章拉丁美洲失智症運動障礙治療症候群市場展望，2018-2031

第八章中東與非洲癡呆症運動障礙治療症候群市場展望，2018-2031

第9章 競爭格局

  • 用於治療運動障礙綜合症的藥物與用於治療伴有其他神經系統異常的進行性癡呆的藥物的熱圖
  • 2023 年公司市場份額分析
  • 競爭力儀表板
  • 公司簡介
    • F. Hoffmann-La Roche, Ltd.
    • Baxter
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi
    • Pfizer, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • AstraZeneca GmbH
    • Abbott Laboratories, Inc.
    • Bristol-Myers Squibb Company

第10章附錄

簡介目錄

Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects

The global market for the treatment of syndromes related to dementia and movement disorders has witnessed remarkable growth in recent years, as the number of individuals affected by these conditions continues to rise. Dementia, a broad category of mental illnesses, and movement disorders, including Parkinson's disease, have presented significant challenges for both patients and caregivers worldwide. According to recent data, approximately 80% of people with movement disorders such as Parkinson's ultimately develop cognitive defects, further emphasizing the need for effective treatments.

Key Market Dynamics:

The increasing aging population across the globe is a driving force behind the rising number of dementia cases. This surge in cases has prompted healthcare providers to explore a range of solutions, including home care services, adult day care services, psychological therapies, medication, and medical devices tailored for last-stage dementia patients. Palliative care units are also witnessing significant growth in response to the demands of patients and their families.

However, despite the collective efforts to ease the burden on those affected by dementia and movement disorders, several challenges persist. These challenges include a stringent regulatory framework, bureaucratic hurdles in the drug approval process, insufficient funding for research and development, and the ongoing struggle to find effective therapeutic management methods. It is noteworthy that most drugs designed to treat these conditions fail to pass Phase III testing, creating a daunting roadblock in the quest to find viable treatments.

Regional Analysis:

Geographically, the North America region is expected to maintain its dominance in the global market for the treatment of syndromes associated with dementia and movement disorders. This dominance is driven by the growing aging population and the increasing incidence of neurodegenerative diseases. Over the next six years, the Asia region is also projected to experience higher growth rates in this market, signaling the need for innovative solutions to meet the rising demand.

Key Market Players:

Major companies at the forefront of the global market for the treatment of dementia and movement disorders include Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others. These industry leaders are dedicated to developing innovative treatments to address the complex challenges presented by these debilitating conditions.

Segment Analysis:

The global market for the treatment of syndromes related to dementia and movement disorders is categorized based on the drugs used for treatment, including progressive dementia, movement disorders, and progressive dementia with certain other neurological abnormalities. These segments encompass drugs tailored for specific conditions, diseases-based therapeutics, and those designed to address associated neurological abnormalities.

As the global community grapples with the growing burden of dementia and movement disorders, the healthcare and pharmaceutical industries are committed to advancing research and delivering effective treatments that enhance the quality of life for affected individuals and their families.

By Drugs Used to Treatment Progressive Dementia

  • Diseases Based Therapeutics Under Progressive Dementia
  • Drugs for Progressive Dementia

By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

  • Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
  • Drugs for Progressive Dementia

By Drugs Used to Treat Movement Disorder Syndrome

  • Diseases Based Therapeutics Under Movement Disorder Syndrome
  • Drugs for Movement Disorder Syndrome

By Region

  • North America
  • Europe
  • Asia

Table of Contents

1. Executive Summary

  • 1.1. Global Treatment Syndromes Dementia Movement Disorders Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 3.1. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 3.1.1.2. Drugs for Progressive Dementia
  • 3.2. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 3.2.1.2. Drugs for Progressive Dementia
  • 3.3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 3.3.1.2. Drugs for Movement Disorder Syndrome
  • 3.4. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 4.1. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 4.1.1.2. Drugs for Progressive Dementia
  • 4.2. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 4.2.1.2. Drugs for Progressive Dementia
  • 4.3. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 4.3.1.2. Drugs for Movement Disorder Syndrome
  • 4.4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 5.1. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 5.1.1.2. Drugs for Progressive Dementia
  • 5.2. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 5.2.1.2. Drugs for Progressive Dementia
  • 5.3. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 5.3.1.2. Drugs for Movement Disorder Syndrome
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 6.1.1.2. Drugs for Progressive Dementia
  • 6.2. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 6.2.1.2. Drugs for Progressive Dementia
  • 6.3. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 6.3.1.2. Drugs for Movement Disorder Syndrome
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 7.1. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 7.1.1.2. Drugs for Progressive Dementia
  • 7.2. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 7.2.1.2. Drugs for Progressive Dementia
  • 7.3. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 7.3.1.2. Drugs for Movement Disorder Syndrome
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 8.1.1.2. Drugs for Progressive Dementia
  • 8.2. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 8.2.1.2. Drugs for Progressive Dementia
  • 8.3. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 8.3.1.2. Drugs for Movement Disorder Syndrome
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drugs Used to Treat Movement Disorder Syndrome vs By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. F. Hoffmann-La Roche, Ltd.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Baxter
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Novartis AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Sanofi
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Pfizer, Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Valeant Pharmaceuticals International, Inc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. AstraZeneca GmbH
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Abbott Laboratories, Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations